BACKGROUND: Pregnancy-associated plasma protein A (PAPP-A) has been suggested as a candidate marker for the identification of unstable plaques in coronary arteries. We assessed the value of PAPP-A for predicting short-term cardiovascular events in a large cohort of patients presenting with cardiac chest pain. METHODS: We included consecutive patients who presented to a teaching hospital in Germany with chest pain of cardiac origin confirmed by coronary angiography. We analyzed PAPP-A levels from serum samples drawn within 30 minutes after arrival in the emergency department or in the catheterization laboratory. Patients were followed for 90 days or until death for major adverse cardiovascular events, defined as the combined outcome of stent thrombosis, myocardial (re)infarction, ischemic stroke or cardiovascular-related death. RESULTS: A total of 2568 patients (mean age [± standard deviation (SD)] 68 ± 11 years; 74% male) presented with cardiac chest pain: 55% had stable angina and 45% had acute coronary syndrome. The PAPP-A levels ranged from 4 to 2154 mIU/L (median 14.0 mIU/L, interquartile range 9.3-25.2 mIU/L). Major adverse cardiovascular events occurred in 203 patients (7.9%). The mean PAPP-A level was higher among patients who had an event than among those who did not (62 ± 156 v. 21 ± 23 mIU/L, p < 0.001). In a multivariable analysis, PAPP-A remained a significant independent predictor of the primary outcome within 90 days (hazard ratio per 1 SD increase in PAPP-A level 1.96, 95% confidence interval 1.74-2.21). The optimal prognostic cutoff value was a PAPP-A level of 34.6 mIU/L. INTERPRETATION: Higher levels of serum PAPP-A were independently associated with an increased short-term risk of cardiovascular events in patients presenting with cardiac chest pain. Further studies are required to validate the use of PAPP-A in routine clinical practice to predict future cardiovascular events.
BACKGROUND:Pregnancy-associated plasma protein A (PAPP-A) has been suggested as a candidate marker for the identification of unstable plaques in coronary arteries. We assessed the value of PAPP-A for predicting short-term cardiovascular events in a large cohort of patients presenting with cardiac chest pain. METHODS: We included consecutive patients who presented to a teaching hospital in Germany with chest pain of cardiac origin confirmed by coronary angiography. We analyzed PAPP-A levels from serum samples drawn within 30 minutes after arrival in the emergency department or in the catheterization laboratory. Patients were followed for 90 days or until death for major adverse cardiovascular events, defined as the combined outcome of stent thrombosis, myocardial (re)infarction, ischemic stroke or cardiovascular-related death. RESULTS: A total of 2568 patients (mean age [± standard deviation (SD)] 68 ± 11 years; 74% male) presented with cardiac chest pain: 55% had stable angina and 45% had acute coronary syndrome. The PAPP-A levels ranged from 4 to 2154 mIU/L (median 14.0 mIU/L, interquartile range 9.3-25.2 mIU/L). Major adverse cardiovascular events occurred in 203 patients (7.9%). The mean PAPP-A level was higher among patients who had an event than among those who did not (62 ± 156 v. 21 ± 23 mIU/L, p < 0.001). In a multivariable analysis, PAPP-A remained a significant independent predictor of the primary outcome within 90 days (hazard ratio per 1 SD increase in PAPP-A level 1.96, 95% confidence interval 1.74-2.21). The optimal prognostic cutoff value was a PAPP-A level of 34.6 mIU/L. INTERPRETATION: Higher levels of serum PAPP-A were independently associated with an increased short-term risk of cardiovascular events in patients presenting with cardiac chest pain. Further studies are required to validate the use of PAPP-A in routine clinical practice to predict future cardiovascular events.
Authors: P Hájek; M Macek; M Hladíková; B Houbová; D Alan; V Durdil; J Fiedler; M Malý; P Ostádal; J Veselka; A Krebsová Journal: Physiol Res Date: 2007-01-02 Impact factor: 1.881
Authors: Jean-Pierre Bassand; Christian W Hamm; Diego Ardissino; Eric Boersma; Andrzej Budaj; Francisco Fernández-Avilés; Keith A A Fox; David Hasdai; E Magnus Ohman; Lars Wallentin; William Wijns Journal: Eur Heart J Date: 2007-06-14 Impact factor: 29.983
Authors: K R Wøjdemann; S O Larsen; L Rode; A Shalmi; K Sundberg; M Christiansen; A Tabor Journal: Scand J Clin Lab Invest Date: 2006 Impact factor: 1.713
Authors: E M Antman; M J Tanasijevic; B Thompson; M Schactman; C H McCabe; C P Cannon; G A Fischer; A Y Fung; C Thompson; D Wybenga; E Braunwald Journal: N Engl J Med Date: 1996-10-31 Impact factor: 91.245
Authors: Conor J McCann; Ben M Glover; Ian B A Menown; Michael J Moore; Jane McEneny; Colum G Owens; Bernie Smith; Peter C Sharpe; Ian S Young; Jennifer A Adgey Journal: Am J Cardiol Date: 2008-10-17 Impact factor: 2.778
Authors: Christoph Etter; Yves Straub; Martin Hersberger; Hans Rudolf Räz; Thomas Kistler; Denes Kiss; Rudolf P Wüthrich; Hans-Jakob Gloor; Daniel Aerne; Patricia Wahl; Richard Klaghofer; Patrice M Ambühl Journal: Eur Heart J Date: 2009-10-21 Impact factor: 29.983
Authors: Kasper K Iversen; Ane S Teisner; Borge Teisner; Anette Kliem; Pia Thanning; Henrik Nielsen; Peter Clemmensen; Peer Grande Journal: Clin Biochem Date: 2009-02-04 Impact factor: 3.281
Authors: H Gutiérrez-Leonard; E Martínez-Lara; A E Fierro-Macías; V M Mena-Burciaga; M D Ronquillo-Sánchez; E Floriano-Sánchez; N Cárdenas-Rodríguez Journal: Ir J Med Sci Date: 2016-10-11 Impact factor: 1.568
Authors: Henri Weidmann; Johannes H Bannasch; Christoph Waldeyer; Apurva Shrivastava; Sebastian Appelbaum; Francisco Miguel Ojeda-Echevarria; Renate Schnabel; Karl J Lackner; Stefan Blankenberg; Tanja Zeller; Mahir Karakas Journal: J Am Heart Assoc Date: 2020-04-23 Impact factor: 5.501
Authors: Alexey A Konev; Alexey V Kharitonov; Fedor N Rozov; Evgeny P Altshuler; Daria V Serebryanaya; Johan Lassus; Veli-Pekka Harjola; Alexey G Katrukha; Alexander B Postnikov Journal: ESC Heart Fail Date: 2020-01-22